Pure Global

A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder - Trial NCT06254612

Access comprehensive clinical trial information for NCT06254612 through Pure Global AI's free database. This Phase 2 trial is sponsored by Sirtsei Pharmaceuticals, Inc. and is currently Recruiting. The study focuses on Major Depressive Disorder. Target enrollment is 456 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06254612
Phase 2
Recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06254612
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder
A Multi-center, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder

Study Focus

Major Depressive Disorder

SP-624

Interventional

drug

Sponsor & Location

Sirtsei Pharmaceuticals, Inc.

Phoenix,Bellflower,Lafayette,Lemon Grove,Oceanside,Torrance,Lauderhill,Miami Lakes,Orlando,Las Vegas,Berlin,Cherry Hill,Portland,Everett, United States of America

Timeline & Enrollment

Phase 2

Mar 19, 2024

Jul 11, 2025

456 participants

Primary Outcome

Change from Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) total score.

Summary

This is a Phase 2B clinical study evaluating the effectiveness and safety of SP-624 as
 compared to placebo in the treatment of adults with Major Depressive Disorder.

ICD-10 Classifications

Recurrent depressive disorder
Recurrent depressive disorder, unspecified
Depressive conduct disorder
Other recurrent depressive disorders
Recurrent depressive disorder, current episode moderate

Data Source

ClinicalTrials.gov

NCT06254612

Non-Device Trial